Altre lingue Ocular Therapeutix, Inc.

Azioni

OCUL

US67576A1007

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 06/06/2024			Variaz. 5gg	Var. 1 gen.
5,2 ^USD	-5,28%		-10,34%	+16,59%

03/06	Ocular Therapeutix taglia il 13% della forza lavoro	MT
31/05	OCULAR THERAPEUTIX, INC. : Piper Sandler mantiene la raccomandazione Buy	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Ocular Therapeutix to Host Investor Day on June 13, 2024	06/06
Ocular Therapeutix® to Host Investor Day on June 13, 2024	05/06
Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/06
Ocular Therapeutix Cutting 13% of Workforce	03/06
Ocular Therapeutix : Costs Associated with Exit/Disposal - Form 8-K	03/06
Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	15/05
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside	09/05
Ocular Therapeutix: Q1 Earnings Snapshot	07/05
Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q1 Revenue $14.8M, vs. Street Est of $15.4M	07/05
Ocular Therapeutix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Ocular Therapeutix™ Reports First Quarter 2024 Results	07/05
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	07/05
Ocular Therapeutix to Present at Two Ophthalmology Meetings, May 4-9, 2024	06/05
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences	06/05
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024	03/05
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024	01/05
Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy	19/04
Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup	18/04
Ocular Therapeutix : Amendment No. 3 to 2019 Inducement Stock Incentive Plan - Form 8-K	18/04
Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall	18/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Ocular Therapeutix, Inc.

Azioni

OCUL

US67576A1007

Altre lingue

Filtri